When you and your doctor make a plan to treat your neuroendocrine ... your tumor has grown: Stage 0. It's only in the outermost layer of the skin. Stage I. The main tumor is no more than 2 cm ...

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Among patients with ...

All neuroendocrine carcinomas (NECs) are grade 3b. The Ki-67 or mitotic index are ways of describing how many cells are dividing. A specialist doctor (pathologist) counts the number of cancer cells ...

progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This follows ITM’s announcement on January 28, 2025, that the trial met its primary endpoint.

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...

The study evaluated the use of RLT earlier as a first-line (or "up front") treatment for patients newly diagnosed with grade 2 or 3 advanced gastrointestinal neuroendocrine tumors. Although ...

Patients diagnosed with high-grade gastroenteropancreatic neuroendocrine tumors (NETs ... in patients with progressive grade 1–2 NETs. Singh et al. therefore evaluated the same combination ...

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a. 177 Lu ...

regardless of primary tumor site or grade. The multicenter, randomized, double-blind, placebo-controlled study enrolled 298 patients in the US. Participants were randomized 2:1 to receive ...